Actos: Effective Type 2 Diabetes Management with Pioglitazone
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.02 (0%) | 🛒 Add to cart |
| 90 | $0.72 | $73.53 $64.50 (12%) | 🛒 Add to cart |
| 120 | $0.67 | $98.04 $79.98 (18%) | 🛒 Add to cart |
| 180 | $0.62 | $147.06 $110.94 (25%) | 🛒 Add to cart |
| 240 | $0.59 | $196.08 $142.76 (27%) | 🛒 Add to cart |
| 360 | $0.57
Best per pill | $294.12 $205.54 (30%) | 🛒 Add to cart |
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.75 | $44.72 (0%) | 🛒 Add to cart |
| 90 | $0.66 | $67.08 $59.34 (12%) | 🛒 Add to cart |
| 120 | $0.62 | $89.44 $73.96 (17%) | 🛒 Add to cart |
| 180 | $0.56 | $134.16 $101.48 (24%) | 🛒 Add to cart |
| 270 | $0.54 | $201.24 $145.34 (28%) | 🛒 Add to cart |
| 360 | $0.52
Best per pill | $268.32 $186.62 (30%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Actos, containing the active ingredient pioglitazone hydrochloride, is an oral antidiabetic medication belonging to the thiazolidinedione class. It is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Pioglitazone works by increasing the body’s sensitivity to insulin, primarily in muscle and adipose tissue, while decreasing hepatic glucose output. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. This medication is a valuable tool in a comprehensive diabetes management plan, often used in combination with other antidiabetic agents like metformin or sulfonylureas when monotherapy does not provide adequate glycemic control.
Features
- Active Ingredient: Pioglitazone Hydrochloride
- Drug Class: Thiazolidinedione (TZD), also known as insulin sensitizers or glitazones
- Available Strengths: 15 mg, 30 mg, and 45 mg film-coated tablets
- Administration: Oral, once daily
- Mechanism of Action: Selective agonist for peroxisome proliferator-activated receptor-gamma (PPAR-γ)
- Primary Action: Improves insulin sensitivity in peripheral tissues (muscle and fat) and reduces glucose production in the liver
Benefits
- Sustained Glycemic Control: Provides consistent, 24-hour reduction of blood glucose and glycosylated hemoglobin (HbA1c) levels.
- Improved Insulin Sensitivity: Addresses a core defect in type 2 diabetes by making the body’s cells more responsive to endogenous insulin.
- Favorable Lipid Profile Impact: Can positively alter lipid metabolism, often leading to increased HDL (“good”) cholesterol and a shift in LDL particle size to a less atherogenic form.
- Convenient Dosing: Once-daily administration supports patient adherence to the treatment regimen.
- Beta-Cell Preservation: Some evidence suggests thiazolidinediones may help preserve pancreatic beta-cell function over the long term.
- Monotherapy and Combination Use: Effective as a standalone treatment or in combination with other major antidiabetic agents like metformin, sulfonylureas, or insulin.
Common use
Actos (pioglitazone) is commonly prescribed for the management of hyperglycemia in adults with type 2 diabetes mellitus. Its use is indicated when glycemic control has not been achieved through diet and exercise alone. It is frequently employed as a second-line agent after metformin or as part of a dual or triple therapy regimen. Clinicians may choose Actos for patients who exhibit significant insulin resistance. It is important to note that its therapeutic effect on blood glucose control is not immediate; maximal response may take several weeks to become apparent. Treatment should be initiated and monitored by a healthcare professional experienced in the treatment of diabetes.
Dosage and direction
The recommended starting dose for Actos monotherapy or combination therapy is 15 mg or 30 mg administered orally once daily, without regard to meals. The dosage may be titrated based on glycemic response, up to a maximum recommended dose of 45 mg once daily.
- Initial Dose: 15 mg or 30 mg once daily.
- Titration: If there is an inadequate glycemic response after a sufficient period (e.g., 8-12 weeks), the dose may be increased.
- Maximum Dose: 45 mg once daily.
- Combination with Insulin: When used in combination with insulin, the insulin dose may need to be decreased by 10% to 25% if the patient reports hypoglycemia, or if their plasma glucose levels fall below 100 mg/dL. Dosage adjustments should not be made more frequently than every 8-12 weeks. Liver enzyme tests should be obtained prior to initiating therapy and periodically per clinical guidance. The dose should not be adjusted in patients with congestive heart failure (NYHA Class I or II); it is contraindicated in patients with Class III or IV cardiac status.
Precautions
- Cardiac Failure: Actos can cause dose-related fluid retention, which may exacerbate or lead to congestive heart failure. Patients should be monitored for signs and symptoms of heart failure (e.g., excessive rapid weight gain, dyspnea, edema).
- Hepatic Effects: Although the risk of drug-induced hepatotoxicity is low, therapy should not be initiated in patients with active liver disease or elevated serum alanine aminotransferase (ALT) levels (>2.5X upper limit of normal). Liver enzymes should be monitored periodically.
- Edema: Pioglitazone is associated with an increased risk of peripheral and pulmonary edema, particularly when used in combination with insulin.
- Hypoglycemia: The risk is increased when Actos is used in combination with other glucose-lowering medications, such as sulfonylureas or insulin.
- Weight Gain: Dose-related weight gain has been observed and can be attributed to fluid retention and fat accumulation.
- Macular Edema: Postmarketing reports have associated TZDs with diabetic macular edema. Patients presenting with visual disturbances should be promptly referred to an ophthalmologist.
- Fractures: Increased incidence of bone fractures, particularly in the distal upper and lower limbs, has been observed in female patients taking pioglitazone.
- Ovulation: In premenopausal anovulatory patients with insulin resistance, pioglitazone therapy may result in resumption of ovulation, increasing the risk of pregnancy. Adequate contraception should be recommended.
Contraindications
Actos is contraindicated in patients with:
- Known serious hypersensitivity to pioglitazone or any other component of the formulation.
- Active bladder cancer. Use is also not recommended in patients with a history of bladder cancer.
- Moderate to Severe Heart Failure (New York Heart Association Class III or IV).
Possible side effect
Like all medications, Actos can cause side effects, although not everybody gets them. Common and serious side effects include:
- Very Common (>10%): Upper respiratory tract infection, headache, myalgia (muscle pain).
- Common (1-10%): Hypoglycemia (especially in combination therapy), weight gain, edema (swelling, particularly of the ankles and legs), sinusitis, pharyngitis, flatulence, asthenia (weakness).
- Uncommon (0.1-1%): Anemia, elevated liver enzymes (ALT), visual disturbance, increased LDL cholesterol.
- Rare (<0.1%): Hepatotoxicity, macular edema, fractures (primarily in women), urticaria, congestive heart failure.
- Frequency Not Known: Bladder cancer, pulmonary edema, angioedema.
Drug interaction
Actos can interact with several other medications, which may necessitate dose adjustments or increased monitoring:
- Strong CYP2C8 Inhibitors (e.g., Gemfibrozil): Can significantly increase pioglitazone plasma concentrations. Concomitant use is not recommended. If necessary, the maximum Actos dose should be limited to 15 mg daily.
- CYP2C8 Inducers (e.g., Rifampin): May decrease pioglitazone plasma concentrations, potentially reducing its efficacy. Monitoring of glycemic control is advised.
- Other Hypoglycemic Agents (e.g., Insulin, Sulfonylureas): Increased risk of hypoglycemia. A lower dose of the concomitant agent may be required.
- Oral Contraceptives (containing Ethinyl Estradiol and Norethindrone): Pioglitazone may reduce the plasma concentrations of these hormones, potentially decreasing contraceptive efficacy. Alternative or additional methods of contraception should be considered.
Missed dose
If a dose of Actos is missed, the patient should take it as soon as they remember on that same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not take a double dose to make up for the forgotten one. Maintaining a consistent daily schedule is important for optimal glycemic control.
Overdose
Experience with pioglitazone overdose in humans is limited. During clinical trials, maximum single doses of 120 mg were administered without observed adverse events. Given its mechanism, the primary risk of overdose is hypoglycemia. In the event of a suspected overdose, blood glucose should be monitored, and appropriate supportive and symptomatic treatment should be initiated. There is no specific antidote for pioglitazone overdose. Hemodialysis is unlikely to be effective due to the drug’s high protein binding.
Storage
- Store Actos tablets at room temperature, between 20°C to 25°C (68°F to 77°F).
- Keep the medication in its original blister pack or bottle to protect it from light and moisture.
- Keep all medicines out of the sight and reach of children and pets.
- Do not use Actos after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various medical resources but may not be comprehensive or reflect the most recent labeling approved by the FDA or other regulatory bodies.
Reviews
“After struggling to control my HbA1c with metformin alone, my endocrinologist added Actos 30 mg. It took about three months, but my numbers came down significantly and have remained stable for over a year. I did experience some initial weight gain and mild ankle swelling, but it subsided. The once-daily pill is very convenient.” – M.K., 58
“As a primary care physician, I find pioglitazone to be a powerful tool for patients with significant insulin resistance. Its effect on HbA1c is robust and durable. I am always very cautious with patient selection, ensuring no history of heart failure or bladder cancer, and I monitor weight and symptoms of edema closely. In the right patient, the benefits far outweigh the risks.” – Dr. A. Evans, MD
“I was prescribed Actos alongside my insulin. The combination worked almost too well initially; I had several hypoglycemic episodes until my insulin dose was reduced. Since then, my blood sugar control has been the best it’s been in years. The fear of potential side effects was concerning at first, but my doctor does regular check-ups to monitor for any issues.” – R.S., 64